Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [1]. Core Insights - The company is positioned as a leader in the chronic disease sector, particularly in cardiovascular treatments, with significant potential for its heart failure drug JK07, expected to contribute over $10 billion in peak sales in the overseas market alone by 2029 [7][36]. - The company has accelerated its innovation transformation, with a focus on a full-cycle product portfolio in chronic diseases, and anticipates achieving 10 billion yuan in revenue by 2029 from its core innovative products [7][36]. - The report highlights the company's robust pipeline, with 118 projects under development, including 74 chemical drugs and 20 biological drugs, indicating a strong commitment to R&D and innovation [29][30]. Summary by Sections 1. Company Overview - The company, established in 1998 and listed in 2009, has become a leader in the chronic disease market, particularly in cardiovascular treatments, leveraging its strong commercialization capabilities [13]. - It operates 8 industrial bases and has established R&D centers in the US and China, covering over 40 countries and regions [13]. 2. Financial Performance - The company forecasts total revenue of 46.43 billion yuan in 2025, with a year-on-year growth of 15.7%, and a net profit of 6.79 billion yuan, reflecting a 12.8% increase [7][36]. - The report indicates that the company’s revenue from innovative drugs is expected to rise significantly, contributing to an overall improvement in profit margins [22]. 3. Product Pipeline and Innovation - The company has a diverse pipeline with a focus on chronic diseases, including metabolic, renal, and orthopedic treatments, with several products already launched and others in advanced clinical stages [30][31]. - JK07, a novel drug targeting heart failure, is highlighted for its potential to disrupt the market, with promising clinical trial results showing significant improvements in left ventricular ejection fraction (LVEF) [36][61]. 4. Market Potential - The heart failure market is projected to grow significantly, with the company’s JK07 expected to capture a substantial share, potentially achieving peak sales of 72.35 billion yuan domestically and $10.93 billion overseas [62]. - The report emphasizes the unmet medical needs in heart failure treatment, suggesting that JK07 could become a leading product in this space [36][44].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a total revenue of 1.227 billion yuan in 2025, representing a year-on-year increase of 23.2%. The net profit attributable to the parent company was 547 million yuan, up 43.0% year-on-year, with a return on equity (ROE) of 17.7%, an increase of 4.0 percentage points year-on-year [7] - All business segments showed positive performance, with significant growth in futures brokerage, asset management, and risk management [7] - The company plans to distribute a dividend of 0.41 yuan per share, a 24.2% increase year-on-year, with a payout ratio of 34.7% [7] Financial Performance Summary - Total revenue projections for the upcoming years are as follows: 2024A: 996 million yuan, 2025A: 1.227 billion yuan, 2026E: 1.410 billion yuan, 2027E: 1.624 billion yuan, and 2028E: 1.872 billion yuan [1] - The net profit attributable to the parent company is projected to grow from 383 million yuan in 2024A to 907 million yuan in 2028E, with year-on-year growth rates of 56.9%, 43.0%, 24.6%, 15.2%, and 15.6% respectively [1] - The earnings per share (EPS) is expected to increase from 0.80 yuan in 2024A to 1.90 yuan in 2028E [1] Business Segment Performance - Futures brokerage revenue for 2025 was 730 million yuan, a year-on-year increase of 15.7%, with a significant rise in client margin scale by 61.6% to 20 billion yuan [7] - The asset management business saw revenue growth of 81.3% to 206 million yuan, with assets under management nearly doubling to 4.63 billion yuan [7] - Risk management business revenue increased by 14.2% to 260 million yuan, with a notable increase in nominal principal for derivative transactions [7] Market Data - The closing price of the company's stock is 22.46 yuan, with a market capitalization of approximately 10.71 billion yuan [5] - The price-to-earnings (P/E) ratio is currently at 19.49, projected to decrease to 12.08 by 2028 [1][20]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a revenue of 4.48 billion yuan for 2025, a decrease of 26% year-on-year, with a net profit attributable to shareholders of 150 million yuan, down 51% year-on-year. The decline in profit was primarily due to cryptocurrency impairment losses and one-time costs related to employee optimization [7] - The gaming segment performed better than expected, with revenue of 3.28 billion yuan, a 17% decline year-on-year. Cost optimization led to a smaller decline in operating profit, which reached 900 million yuan, down only 3% year-on-year. The operating profit margin improved by 3.9 percentage points to 27.4% [7] - The education segment faced short-term pressure, with revenue of 1.2 billion yuan, down 43% year-on-year, and an operating loss of 360 million yuan, which widened from a loss of 300 million yuan in the previous year. The decline was attributed to increased uncertainty in budget allocation from overseas clients [7] - The company is focusing on AI-driven cost reduction and efficiency improvements in its gaming business, while the education business is expected to benefit from a new round of equipment replacement cycles in the medium term [7] Financial Summary - The company’s total revenue is projected to be 4.48 billion yuan in 2025, with a net profit of 150 million yuan. The earnings per share (EPS) is expected to be 0.28 yuan, with a price-to-earnings (P/E) ratio of 28.58 [1][8] - For 2026, the net profit is forecasted to increase to 477.89 million yuan, with an EPS of 0.90 yuan and a P/E ratio of 9.03. By 2028, the net profit is expected to reach 742.16 million yuan, with an EPS of 1.40 yuan and a P/E ratio of 5.82 [1][8] - The company’s gross margin improved to 70.3% in 2025, up 5.1 percentage points year-on-year, while overall operating expenses decreased by 22% [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a significant increase in revenue and net profit for 2025, with total revenue reaching $4.584 billion, a year-on-year growth of 7.2%, and net profit attributable to shareholders at $102 million, up 65.3% year-on-year [9] - The company is positioned as a leader in steer-by-wire technology, successfully launching 57 new customer projects in 2025, including 36 electric vehicle projects, indicating a strong alignment with the trends of electrification and automation in the automotive industry [10] - The company has improved its gross margin to 11.4% in 2025, reflecting a year-on-year increase of 0.9 percentage points, and an adjusted EBITDA margin of 10.3%, also showing a year-on-year improvement [3] Financial Performance Summary - For 2025, the company achieved total revenue of $4.584 billion, with a year-on-year growth of 7.2%, outperforming global vehicle production growth [9] - The net profit for 2025 is projected at $102 million, with a significant increase of 65.3% compared to the previous year [3][9] - The company’s earnings per share (EPS) for 2025 is estimated at $0.04, with a price-to-earnings (P/E) ratio of 15.80 [11] Regional Performance - North America revenue for 2025 is $2.29 billion, up 4.4% year-on-year, despite a decline in regional production [9] - Asia-Pacific revenue is projected at $1.469 billion, reflecting a 9.8% increase, primarily driven by new orders and project launches in China [9] - Revenue from Europe, the Middle East, Africa, and South America is expected to reach $799 million, a year-on-year growth of 11.4%, attributed to new projects and improved regional profitability [9]

中国广核（003816） 证券研究报告·公司点评报告·电力 2025 年报点评：电量稳增电价承压，机制电 价出台彰显核电基荷价值 买入（维持） | [Table_EPS] 盈利预测与估值 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 78,945 | 75,697 | 81,691 | 87,789 | 92,938 | | 同比（%） | (4.37) | (4.11) | 7.92 | 7.46 | 5.87 | | 归母净利润（百万元） | 10,838 | 9,765 | 10,338 | 11,497 | 12,537 | | 同比（%） | 1.06 | (9.90) | 5.87 | 11.21 | 9.05 | | EPS-最新摊薄（元/股） | 0.21 | 0.19 | 0.20 | 0.23 | 0.25 | | P/E（现价&最新摊薄） | 21.43 | 23.79 | 22.47 | 20.20 | 18.53 | 证券分析师 袁理 执业证 ...

买入（维持） | [Table_EPS] 盈利预测与估值 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 996 | 1227 | 1410 | 1624 | 1872 | | 同比（%） | - | 23.2% | 15.0% | 15.2% | 15.3% | | 归母净利润（百万元） | 383 | 547 | 681 | 785 | 907 | | 同比（%） | 56.9% | 43.0% | 24.6% | 15.2% | 15.6% | | EPS-最新摊薄（元/股） | 0.80 | 1.15 | 1.43 | 1.65 | 1.90 | | P/E（现价&最新摊薄） | 26.72 | 19.49 | 16.08 | 13.96 | 12.08 | [Table_Tag] [Table_Summary] 投资要点 2026 年 04 月 01 日 证券分析师 孙婷 证券研究报告·公司点评报告·多元金融 瑞达期货（002961） 2025 年年报点评：归 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Insights - The company achieved a revenue of 1.822 billion yuan in 2025, representing a year-on-year growth of 11.68%, and a net profit attributable to shareholders of 244.64 million yuan, up 24.70% year-on-year [7] - The high-end product strategy continues to yield results, with the company focusing on premiumization and targeting younger consumers, which is expected to drive double-digit growth in liquor sales for 2026 [7] - The company has seen a significant increase in online sales, with e-commerce revenue growing rapidly, contributing to overall revenue growth [7] Financial Projections - Total revenue projections for 2024A to 2028E are as follows: 1.631 billion yuan (2024A), 1.822 billion yuan (2025A), 2.050 billion yuan (2026E), 2.363 billion yuan (2027E), and 2.627 billion yuan (2028E) [1] - Net profit attributable to shareholders is projected to grow from 196.19 million yuan in 2024A to 387.52 million yuan in 2028E, with a year-on-year growth rate of 17.74% in 2024A and 13.41% in 2028E [1] - The earnings per share (EPS) is expected to increase from 0.41 yuan in 2024A to 0.81 yuan in 2028E, reflecting a positive trend in profitability [1] Revenue Breakdown - The liquor revenue for 2025 was 1.77 billion yuan, with a year-on-year increase of 11.8%, and the mid-to-high-end yellow wine revenue accounted for 64.6% of total revenue [7] - The company reported a significant increase in ordinary yellow wine and other liquor revenue, which grew by 21.0% to 630 million yuan, driven by the "billion-level single product" series [7] - Revenue from different regions showed varied performance, with Zhejiang maintaining steady growth while other regions like Jiangsu experienced a decline [7]

证券研究报告·公司点评报告·电力 中国广核（003816） 2025 年报点评：电量稳增电价承压，机制电 价出台彰显核电基荷价值 买入（维持） | [Table_EPS] 盈利预测与估值 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 78,945 | 75,697 | 81,691 | 87,789 | 92,938 | | 同比（%） | (4.37) | (4.11) | 7.92 | 7.46 | 5.87 | | 归母净利润（百万元） | 10,838 | 9,765 | 10,338 | 11,497 | 12,537 | | 同比（%） | 1.06 | (9.90) | 5.87 | 11.21 | 9.05 | | EPS-最新摊薄（元/股） | 0.21 | 0.19 | 0.20 | 0.23 | 0.25 | | P/E（现价&最新摊薄） | 21.43 | 23.79 | 22.47 | 20.20 | 18.53 | [Table_Tag] ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in 2025 met market expectations, with total revenue reaching 6.205 billion yuan, a year-on-year increase of 67.89%, and net profit attributable to shareholders at 1.794 billion yuan, up 89.82% year-on-year [7] - The company has a strong cash flow, with net cash flow from operating activities reaching 2.8 billion yuan, a 124% increase year-on-year, and plans to distribute a cash dividend of 70 yuan per 10 shares, totaling 1.41 billion yuan, which accounts for 78.4% of net profit attributable to shareholders [7] - The company is expected to launch new games that could contribute to revenue growth, including "Lost Castle 2" in mainland China and expansions of existing titles in international markets [7] Financial Summary - Total revenue forecast for 2024A is 3.696 billion yuan, increasing to 6.205 billion yuan in 2025A, and projected to reach 7.141 billion yuan by 2028E [1] - Net profit attributable to shareholders is expected to grow from 944.92 million yuan in 2024A to 2.265 billion yuan in 2028E, with a significant increase of 89.82% in 2025A [1] - The latest diluted EPS is projected to rise from 13.12 yuan in 2024A to 31.45 yuan in 2028E, indicating strong earnings growth [1]

证券研究报告·公司点评报告·光伏设备 帝尔激光（300776） 2025 年报点评：业绩短期承压，光伏+泛半导 体布局可期 买入（维持） | [Table_EPS] 盈利预测与估值 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 2,014 | 2,033 | 2,657 | 3,063 | 3,448 | | 同比（%） | 25.20 | 0.93 | 30.68 | 15.30 | 12.56 | | 归母净利润（百万元） | 527.61 | 519.22 | 678.54 | 791.01 | 895.49 | | 同比（%） | 14.40 | (1.59) | 30.68 | 16.57 | 13.21 | | EPS-最新摊薄（元/股） | 1.93 | 1.89 | 2.48 | 2.89 | 3.27 | | P/E（现价&最新摊薄） | 37.88 | 38.50 | 29.46 | 25.27 | 22.32 | [Table_Tag] [Tab ...